Status Migrainosus - Differentiating Between Responders and Non-responders

• Status: Unknown status
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The main goal of this study is to determine whether it is possible - in the setup of routine clinical care - to identify in individual patients who are clear responders to drug X, common denominators that are absent in individual patients who are non-responders to the same drug, and vice versa. All currently available knowledge about migraine pathophysiology will be utilized, using as much time as is needed to ask as many questions as are necessary, in an attempt to profile clear responders and clear non-responders.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hartford HealthCare
• Treatments: BB 1101; Bupivacaine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Ketorolac; Ketorolac Tromethamine; Naratriptan

Criteria

Inclusion Criteria:

• males and females

• ≥18 years old with no upper age limit

• patients with status migrainosus - defined as a severe migraine headache without aura lasting longer than 72 hours and considered primarily as a complication of migraine

• patients who are willing and able to provide written, informed consent

Exclusion Criteria:

• <18 years old

• unable or unwilling to provide written, informed consent

• females who are pregnant, breastfeeding, or who are trying to become pregnant

• patients who do not speak English

• any medical condition or other reason that in the opinion of the investigators makes the patient unfit or at risk to participate in the study